21 assets in Cerebral Infarction

Therapeutic assets addressing Cerebral Infarction, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cilostazol Cerebral Infarction	Asan Medical Center	P4	BBB (79)
Aspirin Cerebral Infarction	Sclnow Biotechnology Co., Ltd.	P4	BBB (77)
Sovateltide Cerebral Infarction	Pharmazz, Inc.	P4	BBB (75)
Clopidogrel Cerebral Infarction	The Second Hospital of Anhui Medical University	P4	BBB (73)
Atorvastatin Cerebral Infarction	Sclnow Biotechnology Co., Ltd.	P4	BB (65)
Tenecteplase Cerebral Infarction	Second Affiliated Hospital, School of Medicine, Zhejiang University	P3	BB (65)
3-N-BUTYLPHTHALIDE Cerebral Infarction	Qianfoshan Hospital	P4	B (62)
Apixaban Cerebral Infarction	Assistance Publique - Hôpitaux de Paris	P4	B (62)
Tirofiban Cerebral Infarction	Weifang Medical University	P3	B (62)
Colchicinum Cerebral Infarction	Assistance Publique - Hôpitaux de Paris	P3	B (57)
Minocycline Cerebral Infarction	Xiang Luo	P2/3	B (57)
Ticagrelor Cerebral Infarction	Assistance Publique - Hôpitaux de Paris	P3	B (57)
Tocilizumab Cerebral Infarction	Zhujiang Hospital	P3	B (57)
Physiologic Sodium Chloride Solution Cerebral Infarction	Zhujiang Hospital	P3	B (56)
AIR Cerebral Infarction	Turku University Hospital	P2	CCC (53)
Bevifibatide Citrate Cerebral Infarction	Zhujiang Hospital	P2	CCC (53)
Oxygen Cerebral Infarction	Turku University Hospital	P2	CCC (53)
XENON Cerebral Infarction	Turku University Hospital	P2	CCC (53)
Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Cerebral Infarction	Sclnow Biotechnology Co., Ltd.	P1/2	CCC (50)
Pegcetacoplan Cerebral Infarction	Columbia University	P1	CC (41)